Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ Àå±â ÀºÇà ¼ºê½ºÅ©¸³¼Ç ½ÃÀåÀº 2025³â¿¡ 1,851¸¸ ´Þ·¯¸¦ Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ Áß CAGRÀº 5.4%·Î ¼ºÀåÇϸç, 2032³â±îÁö´Â 2,670¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.
Àå±âÀºÇà ±¸µ¶Àº °³ÀÎÀÌ ±¸µ¶ ±â¹Ý Ç÷£À» ÅëÇØ ¹Ì·¡ÀÇ Àå±â ¹× Á¶Á÷ ÀÚ¿øÀ» ÀúÀå, Á¢±Ù, È®º¸ÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â ÇコÄÉ¾î ¼ºñ½º ¸ðµ¨ÀÔ´Ï´Ù. ÀÌ´Â Àå±â, ¼¼Æ÷ ¶Ç´Â Àΰø Á¶Á÷À» ÀáÀçÀûÀÎ ÀÇ·áÀû Ȱ¿ëÀ» À§ÇØ ±ÔÁ¦µÈ º¸Á¸ Á¶°Ç ÇÏ¿¡¼ ¹ÙÀÌ¿À ¹ðÅ·ÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. °¡ÀÔÀÚ´Â Àå±â¿¡ ´ëÇÑ ¿ì¼±Àû Á¢±Ù, ¸ð´ÏÅ͸µ, Àå±â °¡¿ë¼º¿¡ ´ëÇÑ ÃֽŠÁ¤º¸¸¦ Á¦°ø¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ °³³äÀº »ý¸í°øÇÐ, ¸ÂÃãÇü ÀÇ·á, ¹°·ù¸¦ ÅëÇÕÇÏ¿© Àå±âÀûÀÎ Àå±â Áغñ ż¼¸¦ È®º¸ÇÔÀ¸·Î½á ÀüÅëÀûÀÎ ±âÁõÀÚ ´ë±âÀÚ ¸í´Ü¿¡ ´ëÇÑ ÀÇÁ¸µµ¿Í ¿¹Ãø ºÒ°¡´ÉÇÑ ÀÌ½Ä °¡´É¼ºÀ» ÁÙÀÔ´Ï´Ù.
BioInsights¿¡ µû¸£¸é ±¸µ¶ ±â¹Ý Àå±â º¸Á¸ Ç÷§ÆûÀº ºü¸£°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, ¹ÙÀÌ¿À¹ðÅ©´Â ÀÌ½Ä ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ Àå±âÀûÀÎ ¼ºñ½º ¸ðµ¨À» äÅÃÇϰí ÀÖ½À´Ï´Ù.
Àå±âÀÌ½Ä ¼ö¿ä Áõ°¡
Àå±â ÀÌ½Ä ¼ö¿ä Áõ°¡´Â Àå±â ÀºÇà ±¸µ¶ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ½ÅºÎÀü, °£°æÈ, ½ÉÀå ÇÕº´Áõ°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡´Â Àå±â º¸Á¸ ¿ë¾×¿¡ ´ëÇÑ ±ä±ÞÇÑ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. Æò±Õ ¼ö¸íÀÇ ¿¬Àå°ú Àα¸ °í·ÉÈ´Â ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¼ö¼ú ±â¼úÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î ÀÌ½Ä »ýÁ¸À²ÀÌ Çâ»óµÇ¾î ȯÀÚÀÇ Àå±âÀºÇà¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ±× °á°ú, º¸Á¸µÈ Àå±â¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ Á¢±ÙÀ» º¸ÀåÇϱâ À§ÇØ ±¸µ¶ ±â¹Ý ¸ðµ¨ÀÌ °¢±¤À» ¹Þ°í ÀÖ½À´Ï´Ù.
Àå±â º¸Á¸¿¡ ´ëÇÑ À±¸®Àû ¹®Á¦
Àå±â º¸Á¸¿¡ ´ëÇÑ À±¸®Àû ¿ì·Á´Â ÀÌ ½ÃÀåÀÇ Å« ¾ïÁ¦¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. µ¿ÀÇ, ¼ÒÀ¯±Ç, º¸Á¸ Àå±âÀÇ °øÆòÇÑ ºÐ¹è¸¦ µÑ·¯½Ñ ¹®Á¦´Â »çȸÀû, ±ÔÁ¦Àû ³íÀïÀ» °è¼Ó ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. Áö¿ª¿¡ µû¶ó¼´Â ¹®ÈÀû ¹Î°¨¼ºÀÌ Àå±â Àå±âÀºÇàÀÇ º¸±ÞÀ» ´õ¿í °¡·Î¸·°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÎüÁ¶Á÷ÀÇ »ó¾÷È¿¡ ´ëÇÑ ÀDZ¸½É ¶§¹®¿¡ äÅÃÀ» Á¦ÇÑÇÏ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀü¿¡µµ ºÒ±¸Çϰí ÀÌ·¯ÇÑ À±¸®Àû °í·Á°¡ À庮ÀÌ µÇ¾î ´õ ±¤¹üÀ§ÇÑ µµÀÔÀÌ Áö¿¬µÇ°í ÀÖ½À´Ï´Ù. Åõ¸íÇÑ Á¤Ã¥°ú À±¸®Àû ÇÁ·¹ÀÓ¿öÅ©¸¦ ÅëÇØ ÀÌ·¯ÇÑ ¿ì·Á¸¦ ÇØ°áÇÏ´Â °ÍÀº ½ÃÀåÀÇ Áö¼Ó°¡´ÉÇÑ ¼ºÀåÀ» À§ÇØ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.
Àç»ýÀÇ·á ÅëÇÕÀÇ ¼ºÀå
Àç»ýÀÇ·á ÅëÇÕÀº Àå±âÀºÇà °¡ÀÔ¿¡ À¯¸Á ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. Áٱ⼼Æ÷ Ä¡·á, Á¶Á÷°øÇÐ, 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃÀÇ Çõ½ÅÀº ¼Õ»óµÈ Àå±â¸¦ º¹±¸ÇÏ°í ´ëüÇÏ´Â ¹æ¹ýÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. Àå±â º¸Á¸°ú Àç»ý ±â¼úÀ» °áÇÕÇÏ¿© ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â º¸Á¸µÈ Àå±âÀÇ ¼ö¸í°ú »ç¿ë °¡´É¼ºÀ» ¿¬ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À¶ÇÕÀº »õ·Î¿î ¼öÀÔ¿øÀ» âÃâÇϰí ȯÀÚ Ä¡·á °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ±â¾÷°ú Àå±âÀºÇàÀÇ ¿¬±¸°³¹ß Çù·Â¿¡ ÈûÀÔ¾î Àç»ýÀÇ·áÀÇ ÅëÇÕÀº Çõ½ÅÀû ¼ºÀåÀÇ ±æ·Î ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù.
¾ö°ÝÇÑ ÇコÄÉ¾î ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
¾ö°ÝÇÑ ÇコÄÉ¾î ±ÔÁ¦´Â Àå±âÀºÇà ±¸µ¶ ½ÃÀå¿¡ ½É°¢ÇÑ À§ÇùÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. Àå±âÀÇ º¸Á¸, ¿î¼Û, À¯Åë¿¡´Â ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇÑ ¾ö°ÝÇÑ °¡À̵å¶óÀÎÀÌ Àû¿ëµË´Ï´Ù. ±ä ½ÂÀÎ ÀýÂ÷´Â »õ·Î¿î º¸Á¸ ±â¼ú ½ÃÀå ÁøÀÔÀ» Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÄÄÇöóÀ̾𽺠À§¹ÝÀº ¹ýÀû Ã¥ÀÓ°ú dz¹® ÇÇÇØÀÇ À§Çèµµ ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀÎ °¨½ÃÀÇ ´«Ãʸ®¿¡ ³ëÃâµÇ¾î ÀÖÀ¸¹Ç·Î °ø±ÞÀÚ´Â ±ÔÁ¦¿¡ ºÎÇÕÇϱâ À§ÇØ ¸¹Àº ÅõÀÚ¸¦ ÇØ¾ß ÇÕ´Ï´Ù. ±× °á°ú, ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â ȯÀÚ¸¦ º¸È£ÇÏ´Â ÇÑÆí, ±â¼ú Çõ½ÅÀ» Áö¿¬½Ã۰í Àå±âÀºÇà ÇÁ·Î¹ÙÀÌ´õÀÇ ¿î¿µ ºñ¿ëÀ» Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù.
COVID-19 ÆÒµ¥¹ÍÀº Àå±âÀºÇà °¡ÀÔ ½ÃÀå¿¡ ÀÌÁßÀ¸·Î ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. Ãʱ⿡´Â ÀÇ·á ½Ã½ºÅÛÀÇ ¸¶ºñ·Î ÀÎÇØ ÀÌ½Ä ¼ö¼úÀÌ Áö¿¬µÇ¾î º¸Á¸ Àå±â¿¡ ´ëÇÑ ¼ö¿ä°¡ °¨¼ÒÇß½À´Ï´Ù. ±×·¯³ª À̹ø À§±â´Â ¼ö¼ú Àç°³ ÈÄ ¹é·Î±×¸¦ °ü¸®ÇÒ ¼ö Àִ ź·ÂÀûÀÎ º¸Á¸ ¼Ö·ç¼ÇÀÇ Á߿伺À» ºÎ°¢½ÃÄ×½À´Ï´Ù. ºÒÈ®½Ç¼º ¼Ó¿¡¼ º´¿øµéÀÌ Àå±â¿¡ ´ëÇÑ È®½ÇÇÑ Á¢±ÙÀ» ¿øÇßÀ¸¹Ç·Î ±¸µ¶ ¸ðµ¨ÀÇ Ã¤ÅÃÀÌ È®´ëµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ÆÒµ¥¹Í ±â°£ Áß Àú¿Â ÀúÀå ±â¼úÀÇ ¹ßÀüÀÌ °¡¼ÓȵǾú½À´Ï´Ù.
¿¹Ãø ±â°£ Áß Àå±âÀºÇà ºÐ¾ß°¡ °¡Àå Å« ½ÃÀåÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Àå±âÀºÇà ºÐ¾ß´Â ¸¸¼ºÁúȯÀÇ È®»ê°ú Àå±â º¸Á¸ ¿ë¾×¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ³Ãµ¿ º¸Á¸ ±â¼úÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î ÀÌ ºÐ¾ß´Â º´¿ø, ¹ÙÀÌ¿À¹ðÅ©, À̽ļ¾ÅÍ µî¿¡¼ äÅÃÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¤ºÎ Áö¿ø Àå±â º¸Á¸ ±¸»ó Áõ°¡¿Í ±âÁõÀÚ ³×Æ®¿öÅ©ÀÇ È®´ë°¡ ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ Áß Á÷¿ø À£´Ï½º ÆÄÆ®³Ê½Ê ºÐ¾ß°¡ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¿¹Ãø ±â°£ Áß Á÷¿ø À£´Ï½º ÆÄÆ®³Ê½Ê ºÐ¾ß´Â ¿¹¹æÀû °Ç°°ü¸®¿Í Á÷¿ø º¹Áö¿¡ ´ëÇÑ ±â¾÷ÀÇ °ü½É Áõ°¡¿¡ ÈûÀÔ¾î °¡Àå ³ôÀº ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °í¿ëÁÖµéÀÌ °Ç° º¸Çè °¡ÀÔ ¸ðµ¨¿¡ ´ëÇÑ ÅõÀÚ¸¦ È®´ëÇÏ´Â Ãß¼¼¿¡ ÈûÀÔ¾î Àå±âÀºÇà ¼ºñ½º¿ÍÀÇ Á¦ÈÞ°¡ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦ÈÞ´Â Àå¼ö¸¦ ÃËÁøÇÒ »Ó¸¸ ¾Æ´Ï¶ó Á÷¿øµéÀÇ ¹Ì·¡ÁöÇâÀûÀÎ °Ç° ÇÁ·Î±×·¥ Âü¿©¸¦ Àå·ÁÇÕ´Ï´Ù. ¶ÇÇÑ ½ÅÈï °æÁ¦±¹¿¡¼ÀÇ ºü¸¥ º¸±Þ°ú ±¸µ¶ °ü¸®¸¦ À§ÇÑ µðÁöÅÐ Ç÷§ÆûÀÌ °áÇյǾî ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» Å©°Ô °¡¼ÓÈÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¿¹Ãø ±â°£ Áß ¾Æ½Ã¾ÆÅÂÆò¾çÀº ȯÀÚ ¼ö Áõ°¡, ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, ÀÌ½Ä ÀÎÇÁ¶ó¿¡ ´ëÇÑ Á¤ºÎ ÅõÀÚ·Î ÀÎÇØ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àεµ, Áß±¹, ÀϺ» µîÀÇ ±¹°¡¿¡¼´Â ÀÌ½Ä µî·Ï °Ç¼ö°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, º¸Á¸ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Áö¿ª ÀÇ·á °³Çõµµ Àå±âÀºÇà °¡ÀÔ¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ µðÁöÅÐ ÇコÄɾî Ç÷§ÆûÀÇ µµÀÔÀÌ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ¼ºñ½º Á¦°ø ¹üÀ§¸¦ È®ÀåÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ Áß ºÏ¹Ì°¡ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À̴ ÷´ÜÀÎ ÀÇ·á ÀÎÇÁ¶ó, °·ÂÇÑ R&D ÅõÀÚ, Áö¿øÀûÀÎ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿¡ ±âÀÎÇÕ´Ï´Ù. ¹Ì±¹Àº ÃÖ÷´Ü ÀúÀå ±â¼ú°ú ±¸µ¶ ¸ðµ¨ÀÇ º¸±ÞÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. »ýȰ½À°üÀ¸·Î ÀÎÇÑ Àå±âºÎÀü ¹ß»ý·üÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ±â¾÷°ú À̽ļ¾ÅÍ¿ÍÀÇ Çù·Â °ü°èµµ Àå±â º¸Á¸ÀÇ ±â¼ú Çõ½ÅÀ» °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù. ³ôÀº ÀÇ·áºñ ÁöÃâ°ú °·ÂÇÑ µðÁöÅÐ ÅëÇÕ¿¡ ÈûÀÔ¾î ºÏ¹Ì´Â °¡Àå ºü¸¥ ¼ºÀå ±Ëµµ¿¡ ¿À¸¦ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Organ Banking Subscription Market is accounted for $18.51 million in 2025 and is expected to reach $26.7 million by 2032 growing at a CAGR of 5.4% during the forecast period. Organ Banking Subscription is a healthcare service model that enables individuals to preserve, access, or secure future organ or tissue resources through subscription-based plans. It involves biobanking of organs, cells, or engineered tissues under regulated storage conditions for potential medical use. Subscribers may receive priority access, monitoring, and updates regarding organ availability. The concept integrates biotechnology, personalized medicine, and logistics to ensure long-term organ readiness, reducing dependency on conventional donor waiting lists and unpredictable transplant availability.
According to BioInsights, subscription-based organ preservation platforms are expanding rapidly, with biobanks adopting long-term service models to meet rising transplant demands.
Rising demand for organ transplants
The rising demand for organ transplants is a major driver of the organ banking subscription market. Increasing prevalence of chronic diseases such as kidney failure, liver cirrhosis, and heart complications is creating urgent need for organ preservation solutions. Longer life expectancy and aging populations are further fueling demand. Propelled by advancements in surgical techniques, survival rates for transplants are improving, boosting patient reliance on organ banking. Consequently, subscription-based models are gaining traction to ensure continuous access to preserved organs.
Ethical concerns on organ storage
Ethical concerns regarding organ storage represent a significant restraint in this market. Issues surrounding consent, ownership, and equitable distribution of preserved organs continue to raise public and regulatory debates. Cultural sensitivities in some regions further hinder widespread acceptance of long-term organ banking. Moreover, questions about commercialization of human tissues may limit adoption. Despite technological progress, these ethical considerations act as barriers, slowing broader implementation. Addressing these concerns through transparent policies and ethical frameworks is critical for sustainable market growth.
Growth in regenerative medicine integration
The integration of regenerative medicine presents a promising opportunity for organ banking subscriptions. Innovations in stem cell therapies, tissue engineering, and 3D bioprinting are reshaping how damaged organs can be repaired or replaced. By coupling organ preservation with regenerative technologies, service providers can extend the lifespan and usability of stored organs. This convergence creates new revenue streams and enhances patient outcomes. Spurred by R&D collaborations between biotech firms and organ banks, regenerative medicine integration stands as a transformative growth avenue.
Stringent healthcare regulatory frameworks
Stringent healthcare regulations pose a critical threat to the organ banking subscription market. Preservation, transportation, and distribution of organs are subject to rigorous guidelines to ensure safety and efficacy. Lengthy approval processes can delay market entry for new preservation technologies. Additionally, non-compliance risks legal liabilities and reputational damage. Spurred by global scrutiny, providers must invest heavily in regulatory alignment. Consequently, strict frameworks, while safeguarding patients, can slow innovation and increase operational costs for organ banking subscription providers.
The COVID-19 pandemic had a dual impact on the organ banking subscription market. Initially, transplant surgeries were delayed due to overwhelmed healthcare systems, reducing demand for preserved organs. However, the crisis highlighted the importance of resilient storage solutions to manage backlogs once surgeries resumed. Adoption of subscription models grew as hospitals sought reliable access to organs amid uncertainties. Furthermore, advancements in cold storage technologies accelerated during the pandemic
The organ banking segment is expected to be the largest during the forecast period
The organ banking segment is expected to account for the largest market share during the forecast period, owing to the growing prevalence of chronic diseases and rising demand for long-term preservation solutions. Spurred by advancements in cryopreservation technologies, this segment is witnessing heightened adoption across hospitals, biobanks, and transplant centers. Furthermore, the increase in government-backed organ preservation initiatives and expanding donor networks are strengthening market expansion.
The employee wellness partnerships segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the employee wellness partnerships segment is predicted to witness the highest growth rate, impelled by rising corporate focus on preventive healthcare and employee well-being. Fueled by employers' growing investments in health subscription models, partnerships with organ banking services are gaining traction. These alliances not only promote longevity but also encourage employee participation in future-oriented health programs. Moreover, rapid adoption in developed economies, coupled with digital platforms for subscription management, is expected to accelerate segmental growth significantly.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by increasing patient populations, rising chronic disease prevalence, and government investments in transplant infrastructure. Countries like India, China, and Japan are witnessing rising transplant registrations, spurring demand for preservation solutions. Regional healthcare reforms are also improving accessibility to organ banking subscriptions. Moreover, strong adoption of digital healthcare platforms enhances service reach.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to advanced healthcare infrastructure, strong R&D investments, and supportive regulatory frameworks. The U.S. leads with cutting-edge preservation technologies and widespread adoption of subscription-based models. Rising incidence of lifestyle-related organ failures further drives demand. Collaborations between biotech firms and transplant centers also accelerate innovation in organ preservation. Supported by high healthcare spending and robust digital integration, North America is poised for the fastest growth trajectory.
Key players in the market
Some of the key players in Organ Banking Subscription Market include X-Therma Inc., OrganOx Ltd., TransMedics Group, Inc., XVIVO Perfusion AB, Bridge to Life Ltd., Paragonix Technologies, Inc., Cryoport, Inc., BioLife Solutions, Inc., Thermo Fisher Scientific, Inc., Merck KGaA (Sigma-Aldrich), Lonza Group AG, Corning Incorporated, Charter Medical, LLC, OriGen Biomedical, Inc., Miltenyi Biotec, Cytiva (Danaher Corporation), and GenScript Biotech Corporation and Takara Bio Inc.
In August 2025, X-Therma Inc. announced breakthroughs in regenerative organ preservation technology, introducing advanced cold storage solutions and real-time monitoring systems that enhance organ viability during transportation.
In July 2025, OrganOx Ltd. launched a next-generation mobile organ perfusion device that extends liver preservation times while improving transplant success rates, supported by AI-enabled analytics for transplant compatibility.
In June 2025, TransMedics Group, Inc. expanded its Organ Care System portfolio with new capabilities for heart and lung preservation, emphasizing portable, normothermic perfusion for improved organ function.
In May 2025, XVIVO Perfusion AB introduced enhanced machine perfusion systems designed to optimize kidney and lung preservation, integrating novel biocompatible materials and IoT-enabled monitoring.